This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Oct. 31, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that after the market close on
Monday, November 11, 2013, it will release its third quarter fiscal year 2013 financial results. An investor conference call will follow on the same day at
4:30 p.m. ET to discuss those results and provide an update regarding its upcoming meeting with the U.S. Food and Drug Administration's Dermatologic and Ophthalmic Drugs Advisory Committee in
January 2014 to discuss the Company's New Drug Application for ILUVIEN.
The conference call will be hosted by
Dan Myers, President and Chief Executive Officer, and
Rick Eiswirth, Chief Operating Officer and Chief Financial Officer.
To participate in the call, please dial (877) 369-6586 (U.S. and
Canada) or (253) 237-1165 (international). A live webcast will be available on the Investor Relations section of the corporate website at
A replay of the conference call will be available beginning
November 11, 2013 at
7:30 p.m. ET and ending on
November 17, 2013 by dialing (855) 859-2056 (U.S. and
Canada) or (404) 537-3406 (international), Conference ID Number: 92324341. A replay of the webcast will be available on the corporate website for one week, through
November 17, 2013.
About Alimera Sciences, Inc.
Alimera Sciences, Inc., based in
Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently Alimera is focused on diseases affecting the back of the eye, or retina.
ILUVIEN (190 micrograms intravitreal implant in applicator) is a sustained release intravitreal implant used to treat vision impairment associated with chronic DME considered insufficiently responsive to available therapies. Each ILUVIEN implant provides a therapeutic effect of up to 36 months by delivering sustained sub-microgram levels of fluocinolone acetonide (FAc). ILUVIEN is injected in the back of the patient's eye to a position that takes advantage of the eye's natural fluid dynamics. The applicator employs a 25-gauge needle, which allows for a self-sealing wound. In the FAME™ Study, the most frequently reported adverse drug reactions included cataract development and increased ocular pressure. ILUVIEN has not been approved for sale in the U.S. ILUVIEN is approved in the
Spain and pending approval in
Italy. In addition, Alimera has filed with the Medicines and Healthcare Products Regulatory Agency in the
United Kingdom (U.K.) as the Reference Member State for 10 additional European Union country approvals through the Mutual Recognition Procedure.
Investor Contact:ICR, LLC
SOURCE Alimera Sciences, Inc.